國立高雄大學圖資館 |

Language: English

Back

Cardiac amyloidosisdiagnosis and treatment /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Cardiac amyloidosisedited by Michele Emdin ... [et al.].
Reminder of title:	diagnosis and treatment /
other author:	Emdin, Michele.
Published:	Cham :Springer Nature Switzerland :2024.
Description:	viii, 324 p. :ill. (some col.), digital ;24 cm.
Contained By:	Springer Nature eBook
Subject:	HeartDiseases
Online resource:	https://doi.org/10.1007/978-3-031-51757-0
ISBN:	9783031517570$q(electronic bk.)

Cardiac amyloidosisdiagnosis and treatment /
Cardiac amyloidosisdiagnosis and treatment /[electronic resource] :edited by Michele Emdin ... [et al.]. - Cham :Springer Nature Switzerland :2024. - viii, 324 p. :ill. (some col.), digital ;24 cm.

1. Tribute to Claudio Rapezzi -- 2. Giampaolo Merlini and the Pavia School -- 3. A brief history of amyloidosis -- 4. Pathophysiology, classification and epidemiology of amyloidosis -- 5. Amyloid light chain (AL) amyloidosis -- 6. Hereditary transthyretin amyloidosis -- 7. Wild-type ATTR amyloidosis -- 8. Electrocardiographic patterns -- 9. Echocardiography: a gatekeeper to diagnosis -- 10. Cardiovascular magnetic resonance: characterization of myocardial involvement -- 11. Biomarkers: monoclonal protein and indicators of cardiac damage -- 12. Plasma transthyretin and its ligands -- 13. Cardiac Scintigraphy with Bone-Avid Tracers - Old and New Applications -- 14. PET-CT: a tool for etiological diagnosis -- 15. The role of tissue biopsy: identification of the amyloid precursor and beyond -- 16. From red flags to diagnosis -- 17. Risk prediction and follow-up -- 18. Differential diagnoses in clinical mimics -- 19. Applications of Artificial Intelligence in Amyloidosis -- 20. Treatment of amyloid light-chain amyloidosis -- 21. Treatment of ATTR amyloidosis: from stabilizers to gene-editing -- 22. Treatment of cardiac complications -- 23. Monitoring disease progression and response to disease-modifying treatments -- 24. Cardiac amyloidosis: open issues and future perspectives.

Cardiac amyloidosis (CA) is caused by the accumulation of amyloid fibrils in the extracellular space of the myocardium, with clinical manifestations including conduction disturbances and heart failure. CA has traditionally been considered a rare disease, lacking effective therapies and with a poor prognosis, but in recent years, increased possibilities for non-invasive diagnosis and greater awareness of the disease have led to the identification of a growing number of cases, challenging the concept of CA as a rare disease. This is why the ability to recognise and manage patients with CA should become part of the core curriculum of cardiologists, but also of internal medicine specialists, neurologists, nephrologists, haematologists, and general practitioners. This book, written by leading experts in the field, will provide the state-of-the-art in the diagnosis and management of CA and will also discuss the latest research developments and future research directions. The volume appears to be a timely one, given the great interest of clinicians and researchers in CA and the exponential increase in publications in recent year, and will be of interest to cardiologists, internal medicine and other disciplines specialists who may encounter patients with CA in their clinical practice, as well as general practitioners.

ISBN: 9783031517570$q(electronic bk.)

Standard No.: 10.1007/978-3-031-51757-0doiSubjects--Topical Terms:

318254
Heart
--Diseases

LC Class. No.: RC683

Dewey Class. No.: 616.12075

Cardiac amyloidosisdiagnosis and treatment /
LDR:03600nmm a22003255a 4500 001 665405
003 DE-He213
005 20240329053032.0
006 m d
007 cr nn 008maaau
008 241219s2024 sz s 0 eng d
020 $a 9783031517570$q(electronic bk.)
020 $a 9783031517563$q(paper)
024 7 $a 10.1007/978-3-031-51757-0 $2 doi
035 $a 978-3-031-51757-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RC683
072 7 $a MB $2 bicssc
072 7 $a MED000000 $2 bisacsh
072 7 $a MB $2 thema
082 0 4 $a 616.12075 $2 23
090 $a RC683 $b .C267 2024
245 0 0 $a Cardiac amyloidosis $h [electronic resource] : $b diagnosis and treatment / $c edited by Michele Emdin ... [et al.].
260 $a Cham : $b Springer Nature Switzerland : $b Imprint: Springer, $c 2024.
300 $a viii, 324 p. : $b ill. (some col.), digital ; $c 24 cm.
505 0 $a 1. Tribute to Claudio Rapezzi -- 2. Giampaolo Merlini and the Pavia School -- 3. A brief history of amyloidosis -- 4. Pathophysiology, classification and epidemiology of amyloidosis -- 5. Amyloid light chain (AL) amyloidosis -- 6. Hereditary transthyretin amyloidosis -- 7. Wild-type ATTR amyloidosis -- 8. Electrocardiographic patterns -- 9. Echocardiography: a gatekeeper to diagnosis -- 10. Cardiovascular magnetic resonance: characterization of myocardial involvement -- 11. Biomarkers: monoclonal protein and indicators of cardiac damage -- 12. Plasma transthyretin and its ligands -- 13. Cardiac Scintigraphy with Bone-Avid Tracers - Old and New Applications -- 14. PET-CT: a tool for etiological diagnosis -- 15. The role of tissue biopsy: identification of the amyloid precursor and beyond -- 16. From red flags to diagnosis -- 17. Risk prediction and follow-up -- 18. Differential diagnoses in clinical mimics -- 19. Applications of Artificial Intelligence in Amyloidosis -- 20. Treatment of amyloid light-chain amyloidosis -- 21. Treatment of ATTR amyloidosis: from stabilizers to gene-editing -- 22. Treatment of cardiac complications -- 23. Monitoring disease progression and response to disease-modifying treatments -- 24. Cardiac amyloidosis: open issues and future perspectives.
520 $a Cardiac amyloidosis (CA) is caused by the accumulation of amyloid fibrils in the extracellular space of the myocardium, with clinical manifestations including conduction disturbances and heart failure. CA has traditionally been considered a rare disease, lacking effective therapies and with a poor prognosis, but in recent years, increased possibilities for non-invasive diagnosis and greater awareness of the disease have led to the identification of a growing number of cases, challenging the concept of CA as a rare disease. This is why the ability to recognise and manage patients with CA should become part of the core curriculum of cardiologists, but also of internal medicine specialists, neurologists, nephrologists, haematologists, and general practitioners. This book, written by leading experts in the field, will provide the state-of-the-art in the diagnosis and management of CA and will also discuss the latest research developments and future research directions. The volume appears to be a timely one, given the great interest of clinicians and researchers in CA and the exponential increase in publications in recent year, and will be of interest to cardiologists, internal medicine and other disciplines specialists who may encounter patients with CA in their clinical practice, as well as general practitioners.
650 0 $a Heart $x Diseases $x Diagnosis. $3 318254
650 0 $a Heart $x Diseases $x Treatment. $3 338157
650 0 $a Amyloidosis. $3 561373
650 1 4 $a Health Sciences. $3 911835
700 1 $a Emdin, Michele. $3 261947
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-3-031-51757-0
950 $a Medicine (SpringerNature-11650)